News Quantified

ACAD – acadia pharmaceuticals inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union [Yahoo! Finance]

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

-3.0%

BEAT

2.5%

BEAT

14.3%

BEAT

1.8%

BEAT

Needham & Company LLC

Form 8-K ACADIA PHARMACEUTICALS For: Jan 13

Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Kihara James

Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Schneyer Mark C.

Form SCHEDULE 13G/A ACADIA PHARMACEUTICALS Filed by: RTW INVESTMENTS, LP

Form 4 ACADIA PHARMACEUTICALS For: Nov 10 Filed by: Daly James M

Top News Gainers

9/9 ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis 61.4%

7/31 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.460 ActVsEst 0.080 - Beat 16.6%

12/4 Acadia Pharma's psychosis drug proven better than placebo in dementia patients [Reuters] 10.9%

11/11 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019 9.3%

9/14 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.0%

10/19 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.1%

4/2 Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha] 6.8%

5/3 ACADIA -3.5% after 40.2M-share shelf registration [Seeking Alpha] 6.7%

9/9 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Piper Jaffray Companies from $35.00 to $56.00. They now have an "overweight" rating on the stock. 6.5%

3/3 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome 6.1%

Top News Decliners

9/9 Form 8-K ACADIA PHARMACEUTICALS For: Sep 09 -22.3%

7/22 Acadia's schizophrenia treatment fails to meet main goal of late-stage study [Reuters] -14.4%

1/13 Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 -9.1%

8/31 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.7%

5/1 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.4%

9/11 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -7.3%

12/6 Form 4 ACADIA PHARMACEUTICALS For: Dec 05 Filed by: DAVIS STEPHEN -6.4%

2/27 ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.3%

9/25 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 -6.0%

3/5 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day